ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2091

Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network

Gabriel Figueroa Parra1, Jose Meade Aguilar1, Cynthia Crowson2, Cassondra Hulshizer1, Tina Gunderson1, Alanna Chamberlain1 and Ali Duarte-Garcia1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Comorbidity, Epidemiology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster III: Outcomes

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: As the life expectancy of patients with systemic lupus erythematosus (SLE) improves, comorbidities have become more critical. Multimorbidity (MM2+) is defined as the coexistence of two or more chronic diseases. There is limited knowledge about the prevalence of MM2+ at SLE diagnosis and its development after SLE onset. We aimed to assess the prevalence (burden) of MM2+ at SLE classification and its incidence after SLE onset in a community population-based cohort of SLE patients compared to matched controls.

Methods: Incident SLE patients meeting the 2019 EULAR/ACR classification criteria in a population-based cohort, matched 1:1 on sex, age, and county of residence to non-SLE comparators from the same underlying population, were included. We assembled 57 chronic condition categories based upon previously described 44 categories (England, BR. ARD 2020). The 13 additional categories were added based on the SLICC/ACR damage index (SDI) or were otherwise considered relevant to SLE. MM2+ was defined as the presence of two or more chronic conditions categories. Five or more chronic conditions (MM5+) was used as a secondary definition. Comorbidities were assessed using ICD codes within a two-year lookback period to determine the burden at SLE classification. Two or more codes at least 30 days apart were required to count a comorbidity.

The categories were stratified as “SLE-related” if they were included in the SDI; the rest were classified as “non-SLE-related.” Logistic regression models were used to estimate the odds ratio (OR) at baseline. Aalen-Johansen methods were used to estimate the cumulative incidence of MM2+ and MM5+ among patients with SLE and comparators. Cox proportional hazards models adjusted for age, sex, and calendar year of incidence were used to estimate the probability of developing MM2+ and MM5+ in both groups. OR p-values were false discovery rate (FDR)-adjusted.

Results: We included 268 patients with SLE and 264 comparators. The median age was 47 years; 80% and 81% were female and 80% and 89% were non-Hispanic White, respectively.

At SLE classification, 56.3% of the patients with SLE already had MM2+ compared to 37.9% of non-SLE comparators (OR 2.34, 95% CI 1.62, 3.40). The burden of MM2+ given by non-SLE-related conditions was higher (47.8% in patients with SLE and 32.6% in comparators) than the burden given by SLE-related conditions (17.2% and 6.8%, respectively). Results were similar using the MM5+ definition. (Table 1)

After SLE classification, the risk of developing MM2+ was 2.5-fold higher among patients with SLE than comparators (hazard ratio (HR) 2.46, 95% CI 1.84, 3.29); the risk given by SLE-related conditions was substantially higher (HR 3.08, 95% CI 2.29, 4.15) than the risk given by non-SLE-related conditions (HR 1.93, 95% CI, 1.47, 2.53). Results were similar using the MM5+ definition (Figure 1).

Conclusion: Patients with SLE have a higher burden of multimorbidity even before SLE classification, driven predominantly by non-SLE-associated comorbidities. SLE-specific comorbidities drive the elevated risk of multimorbidity after SLE classification, but chronic conditions not traditionally associated with SLE are also elevated.

Supporting image 1

Table 1. Burden of multimorbidity (MM2+) and substantial multimorbidity (MM5+) among patients with systemic lupus erythematosus (SLE) and matched comparators at SLE classification. OR = odds ratio

Supporting image 2

Figure 1. A) Cumulative incidence of multimorbidity (MM2+) and substantial multimorbidity (MM5+) among patients with systemic lupus erythematosus (SLE; solid line) after diagnosis and matched comparators (dashed line). B) MM2+ and MM5+ given by chronic conditions related to SLE and C) by conditions not traditionally related to SLE. Cox models adjusted for age, sex, and calendar year.


Disclosures: G. Figueroa Parra, None; J. Meade Aguilar, None; C. Crowson, None; C. Hulshizer, None; T. Gunderson, None; A. Chamberlain, None; A. Duarte-Garcia, None.

To cite this abstract in AMA style:

Figueroa Parra G, Meade Aguilar J, Crowson C, Hulshizer C, Gunderson T, Chamberlain A, Duarte-Garcia A. Burden and Incidence of Multimorbidity in Systemic Lupus Erythematosus in a Community Population-Based Cohort: The Lupus Midwest Network [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/burden-and-incidence-of-multimorbidity-in-systemic-lupus-erythematosus-in-a-community-population-based-cohort-the-lupus-midwest-network/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/burden-and-incidence-of-multimorbidity-in-systemic-lupus-erythematosus-in-a-community-population-based-cohort-the-lupus-midwest-network/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology